These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24055353)

  • 1. The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged ≥6 months to <36 months: a comparison of published and unpublished studies.
    Kaczmarek MC; Duong UT; Ware RS; Lambert SB; Kelly HA
    Vaccine; 2013 Nov; 31(46):5359-65. PubMed ID: 24055353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
    Tse A; Tseng HF; Greene SK; Vellozzi C; Lee GM;
    Vaccine; 2012 Mar; 30(11):2024-31. PubMed ID: 22361304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children.
    Li-Kim-Moy J; Yin JK; Rashid H; Khandaker G; King C; Wood N; Macartney KK; Jones C; Booy R
    Euro Surveill; 2015 Jun; 20(24):. PubMed ID: 26111238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance.
    Petousis-Harris H; Poole T; Turner N; Reynolds G
    Vaccine; 2012 Jul; 30(33):4945-52. PubMed ID: 22664224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.
    Rosenberg M; Sparks R; McMahon A; Iskander J; Campbell JD; Edwards KM
    Vaccine; 2009 Jul; 27(32):4278-83. PubMed ID: 19450636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults.
    Leeb A; Carcione D; Richmond PC; Jacoby P; Effler PV
    Vaccine; 2011 Oct; 29(45):7920-4. PubMed ID: 21864621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Aug; 59(31):989-92. PubMed ID: 20703207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.
    Kawai AT; Li L; Kulldorff M; Vellozzi C; Weintraub E; Baxter R; Belongia EA; Daley MF; Jacobsen SJ; Naleway A; Nordin JD; Lee GM
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):548-53. PubMed ID: 24497128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms.
    Blyth CC; Currie AJ; Wiertsema SP; Conway N; Kirkham LA; Fuery A; Mascaro F; Geelhoed GC; Richmond PC
    Vaccine; 2011 Jul; 29(32):5107-13. PubMed ID: 21640152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study.
    Stowe J; Andrews N; Bryan P; Seabroke S; Miller E
    Vaccine; 2011 Nov; 29(51):9467-72. PubMed ID: 22019757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine.
    Stockwell MS; Broder K; LaRussa P; Lewis P; Fernandez N; Sharma D; Barrett A; Sosa J; Vellozzi C
    JAMA Pediatr; 2014 Mar; 168(3):211-9. PubMed ID: 24395025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oil-in-water emulsion adjuvant with influenza vaccine in young children.
    Vesikari T; Knuf M; Wutzler P; Karvonen A; Kieninger-Baum D; Schmitt HJ; Baehner F; Borkowski A; Tsai TF; Clemens R
    N Engl J Med; 2011 Oct; 365(15):1406-16. PubMed ID: 21995388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink.
    Glanz JM; Newcomer SR; Hambidge SJ; Daley MF; Narwaney KJ; Xu S; Lee GM; Baggs J; Klein NP; Nordin JD; Naleway AL; Belongia EA; Weintraub ES
    Arch Pediatr Adolesc Med; 2011 Aug; 165(8):749-55. PubMed ID: 21810637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents.
    Lambert SB; Chuk LM; Nissen MD; Nolan TM; McVernon J; Booy R; Heron L; Richmond PC; Walls T; Marshall HS; Reynolds GJ; Hartel GF; Hu W; Lai MH
    Influenza Other Respir Viruses; 2013 Sep; 7(5):676-85. PubMed ID: 23551933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fever following administration of two inactivated influenza vaccines--a survey of parents of New Zealand infants and children 5 years of age and under.
    Petousis-Harris H; Poole T; Booy R; Turner N
    Vaccine; 2011 Apr; 29(16):2933-7. PubMed ID: 21338679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
    Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.